About Us

Neurodyn Cognition Inc. is a spin-out company of Neurodyn Life Sciences Inc. – a special purpose company established to commercialize Memogain®

MemogainRender2 copy



  • A next generation pro-drug of an approved AD drug (Reminyl)
  • Alpha-7 potentiation – main mechanism
  • No side effects, high brain delivery
  • Potent disease modification demonstrated pre-clinically
  • Potential rapid EU approval



Get the latest on Neurodyn Cognition from CEO, Kenneth Cawkell, in this feature presentation at Noble Capital Markets’ 14th Annual Investor Conference.



WordPress Login Protected by Clef